Highlights: Transformative quarter pivoting PharmAust’s focus...

Highlights:
 Transformative quarter pivoting PharmAust’s focus to neurodegenerative diseases
 Board of Directors skills refreshed and enhanced with the appointments of a new,
experienced Chair, NEDs and CEO
 Executive leadership team enhanced with the key appointments in manufacturing,
science, and business development
 Monepantel granted Orphan Drug Designation for the treatment of ALS by the US FDA
 PharmAust granted Small and Medium-Sized Enterprise status by the EMA
 Open-Label Extension Study receives final Ethics Committee approval and completes
enrolment
 Additional impressive survival data for patients who continue to receive treatment with
monepantel from the Phase 1 MEND Study
 Berry Consultants independently presents positive Phase 1 MEND Study data at major
international conference
 Acceptance of monepantel into the prestigious HEALEY ALS Platform Trial provides
independent validation of monepantel’s potential, post quarter
 Successful $10 million capital raise via placement to new and existing institutional and
sophisticated investors
 Share Purchase Plan exceeds expectations and raising a further $7.8 million
 Strong cash balance of $10.66 million as at 30 June, plus $7.8 million from completed
SPP

What's the ETA on the Tablets,,, need those before we start to move forward again...? NZT